(Q39439890)

12 September 2017

title

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study (English)

1 reference

12 September 2017

1 reference

3

1 reference

12 September 2017

Dahlof C

1

1 reference

12 September 2017

Hogenhuis L

2

1 reference

12 September 2017

Petit H

4

1 reference

12 September 2017

Ribbat J

5

1 reference

12 September 2017

Schoenen J

6

1 reference

12 September 2017

Boswell D

7

1 reference

12 September 2017

Fuseau E

8

1 reference

12 September 2017

Hassani H

9

1 reference

12 September 2017

Winter P

10

1 reference

12 September 2017

publication date

1 September 1998

1 reference

European Journal of Neurology

12 September 2017

published in

1 reference

12 September 2017

volume

5

1 reference

12 September 2017

issue

5

1 reference

12 September 2017

page(s)

469-477

1 reference

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1998.550469.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1998.550469.X

Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1998.550469.X

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1998.550469.X

10.1046/J.1468-1331.1998.550469.X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference